Department of Nuclear Medicine, Ankara Oncology Research and Training Hospital, Ankara, Turkey.
Ann Nucl Med. 2013 Oct;27(8):756-63. doi: 10.1007/s12149-013-0745-1. Epub 2013 Jun 21.
The objective of this retrospective study was to evaluate the prognostic significance of volume-based metabolic markers of PET/CT along with clinical characteristics in patients with in-operable cervical carcinoma.
Fifty-eight patients with cervical carcinoma (stage IIB-IVB) underwent FDG PET/CT for pretreatment evaluation and included in this study. Patients were staged according to International Federation of Gynecology and Obstetrics [FIGO] system. After chemoradiation therapy, patients were evaluated for persistent disease (PD) by clinical examinations, smear tests, pelvic MRI and PET/CT. Based upon follow-up results, clinical characteristics (patient age, tumor histology, FIGO stage) and PET/CT findings such as presence of PET-positive pelvic/para-aortic lymph nodes (LN), metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake values (SUVmax) of tumor and lymph nodes were analyzed for disease persistence. Survival analysis for disease-free survival and overall survival was performed with Kaplan-Meier method using PET findings and clinical characteristics.
At the time of last follow-up (mean: 22 ± 12.6 months, range 6-48), 38 patients (65 %) had PD, 20 patients (35 %) had no evidence of disease (NED). Patient age, tumor histology, MTV, TLG and tumor SUVmax did not differ between groups. The frequency of PET-positive pelvic/para-aortic lymph nodes (84 vs. 60 %, p = 0.03), LN SUVmax (10.2 vs. 6.5, p = 0.02), and FIGO stage differed significantly between PD and NED groups. Cox proportional hazards model demonstrated advanced FIGO stage and the presence of PET-positive para-aortic LN were independent predictors for PD. Both disease-free survival and overall survival curves showed progressive worsening as the disease advanced, p = 0.015. PET LN status was the most important prognostic indicator for disease-free survival and overall survival. The worst outcome curves were detected for patients with PET-positive para-aortic lymph nodes among all patients, p = 0.03.
Advanced FIGO stage and the presence of FDG-avid para-aortic lymph nodes on pretreatment PET/CT are significant prognostic biomarkers for PD and decreased overall survival in patients with in-operable cervical carcinoma independent from MTV, TLG, tumor and lymph node SUVmax.
本回顾性研究旨在评估 PET/CT 容积代谢标志物与不能手术的宫颈癌患者临床特征的预后意义。
本研究纳入了 58 例接受 FDG PET/CT 治疗的宫颈癌(ⅡB-IVB 期)患者。患者根据国际妇产科联盟(FIGO)系统进行分期。放化疗后,通过临床检查、涂片检查、盆腔 MRI 和 PET/CT 评估持续性疾病(PD)。根据随访结果,分析临床特征(患者年龄、肿瘤组织学、FIGO 分期)和 PET/CT 发现,如存在 FDG 阳性盆腔/腹主动脉旁淋巴结(LN)、代谢肿瘤体积(MTV)、总病灶糖酵解(TLG)、肿瘤和淋巴结的最大标准化摄取值(SUVmax)与疾病持续性的关系。采用 Kaplan-Meier 法分析无病生存和总生存的生存分析,使用 PET 发现和临床特征。
在最后一次随访时(平均:22±12.6 个月,范围 6-48 个月),38 例(65%)患者出现 PD,20 例(35%)患者无疾病证据(NED)。组间患者年龄、肿瘤组织学、MTV、TLG 和肿瘤 SUVmax 无差异。PET 阳性盆腔/腹主动脉旁淋巴结(84%比 60%,p=0.03)、LN SUVmax(10.2 比 6.5,p=0.02)和 FIGO 分期在 PD 和 NED 组之间有显著差异。Cox 比例风险模型显示,FIGO 分期较高和存在 FDG 阳性腹主动脉旁 LN 是 PD 的独立预测因素。无病生存和总生存曲线均显示随着疾病的进展而逐渐恶化,p=0.015。PET LN 状态是无病生存和总生存的最重要预后指标。所有患者中,PET 阳性腹主动脉旁淋巴结患者的预后最差,p=0.03。
术前 PET/CT 上 FIGO 分期较高和 FDG 摄取阳性的腹主动脉旁淋巴结是不能手术的宫颈癌患者 PD 和总生存率降低的重要预后生物标志物,独立于 MTV、TLG、肿瘤和淋巴结 SUVmax。